Drugs and drug regimens used
| Patients | |
| Drug regimens (n=25) | |
| Docetaxel | 24 (21) |
| Paclitaxel | 9 (8) |
| Erlotinib | 17 (15) |
| Vemurafenib | 1 (1) |
| Gemcitabine | 26 (23) |
| Vinorelbine | 8 (7) |
| Pemetrexed | 6 (5) |
| Afatinib | 3 (3) |
| Abemaciclib | 1 (1) |
| Platin docetaxel | 1 (1) |
| Platin pemetrexed | 4 (3) |
| Platin gemcitabine | 1 (1) |
| Platin paclitaxel | 1 (1) |
| Platin paclitaxel bevacizumab | 1 (1) |
| Platin vinorelbine | 1 (1) |
| Platin etoposide | 1 (1) |
| Paclitaxel trastuzumab | 1 (1) |
| Vinorelbin trastuzumab | 1 (1) |
| Abemaciclib necitumumab | 1 (1) |
| Pemetrexed bevacizumab | 1 (1) |
| Paclitaxel bevacizumab | 2 (2) |
| Pertuzumab afatinib | 1 (1) |
| Paclitaxel erlotinib | 1 (1) |
| Cytarabine | 1 (1) |
| Everolimus | 1 (1) |
| Drugs (n=18) | |
| Docetaxel | 25 (22) |
| Paclitaxel | 15 (13) |
| Erlotinib | 18 (16) |
| Vemurafenib | 1 (1) |
| Gemcitabine | 27 (23) |
| Vinorelbine | 10 (9) |
| Pemetrexed | 11 (10) |
| Afatinib | 4 (3) |
| Abemaciclib | 2 (2) |
| Trastuzumab | 2 (2) |
| Necitumumab | 1 (1) |
| Bevacizumab | 4 (3) |
| Vemurafenib | 1 (1) |
| Pertuzumab | 1 (1) |
| Etoposide | 1 (1) |
| Platin | 10 (9) |
| Everolimus | 1 (1) |
| Cytarabine | 1 (1) |
Data are presented as n (%), unless otherwise stated.